Stocks Health care ATHE

NASDAQ · Health care

Alterity Therapeutics Ltd (ATHE)

It posted a net loss of A$12.1M. At June 30, 2025 it held A$33.2M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on August 28, 2026.

Watch ATHE in 60 seconds

What Alterity Therapeutics Ltd does

Alterity Therapeutics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ATHE.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in AUD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Alterity Therapeutics Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 25, 2026
   Foreign issuer update 6-K
2. September 23, 2026
   Foreign issuer update 6-K
3. September 18, 2026
   Employee stock plan registration S-8
4. September 18, 2026
   Foreign issuer update 6-K
5. September 16, 2026
   Foreign issuer update 6-K
6. September 8, 2026
   Foreign issuer update 6-K
7. September 8, 2026
   Foreign issuer update 6-K
8. September 3, 2026
   Foreign issuer update 6-K
9. September 2, 2026
   Foreign issuer update 6-K
10. September 2, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 8, 2026. Insider transactions on SEC

Insider trades

What the people running Alterity Therapeutics Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $23.8K worth of shares on the open market in the last 90 days and sold none.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ATHE

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: Jpmorgan Chase & Co. 4% (May 5, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 191,340 shares in total, about $669.7K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ATHE

What does Alterity Therapeutics Ltd do?

Alterity Therapeutics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ATHE.

Is Alterity Therapeutics Ltd profitable?

No. In fiscal 2025 it reported a net loss of A$12.1M.

When did Alterity Therapeutics Ltd last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on August 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the foreign issuer update from September 25, 2026.

Similar companies

Compare ATHE with

Compare ATHE with any company

Follow ATHE

Get an email when Alterity Therapeutics Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow ATHE: get an email when it files

Where the numbers come from

Financial figures are the values Alterity Therapeutics Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.